The REVEAL study has been assessing the sensitivity and specificity of iodine 124 evuzamitide (I 124 evuzamitide), a PET agent capable of visualizing signs of cardiac amyloidosis on imaging.
Kevin Accola, MD, spoke to Cardiovascular Business about new 10-year data on the performance of surgical valves featuring Resilia tissue. The findings are good news for Edwards Lifesciences, which also includes the tissue on many of its TAVR devices.
Artificial intelligence tools have proven to be beneficial in detecting pulmonary nodules on chest CTs of adults, but less is known about their utility in pediatric populations.
Cardiologists and other physicians have always believed cardiac transthyretin amyloidosis, a progressive heart condition associated with a high mortality rate, was irreversible. Now, though, new evidence suggests that there may be hope.
Motives for the hesitancy are several—transportation concerns, informational inadequacies, historical wrongs—but effective resolutions can be quite simple.
Cedars-Sinai researchers are developing a deep-learning algorithm to personalize patient cardiac risk predictions in a patient-friendly, graphical report.
Someday, getting an MRI exam could be as simple as having food delivered to your door—at least that is the hope of a group of experts at the University of Minnesota who are working on a compact system said to be small enough to sit in the bed of a truck.
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/top_stories/public/2024-09/istock-1209664264.jpg.webp?itok=gQInU1vO)
